Zosano Pharma Corp
ZSAN evidence brief
What we can confirm
- BioSniper Score:
- 6.4 / 10
- Lead Asset:
- m207 (BLA Filed)
What it means
What to watch
Prepared research question
What matters most for ZSAN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
m207 (BLA Filed)
Next Catalyst
—
Tracking 1 pipeline candidate for Zosano Pharma Corp.
Run Zosano Pharma Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zosano Pharma Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: BLA Filed
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is Zosano Pharma Corp's lead drug candidate?
Zosano Pharma Corp's most advanced tracked candidate is m207 (BLA Filed) for Migraine.
Who is the CEO of Zosano Pharma Corp?
Directors Steven Lo is the chief executive officer of Zosano Pharma Corp (ZSAN).
What therapeutic areas does Zosano Pharma Corp focus on?
Zosano Pharma Corp develops therapies across Neurology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.